The aberrant activation of GSK-3β in AD leads to Tau protein hyperphosphorylation, preventing its binding to microtubules and resulting in neurodegeneration, ultimately contributing to the pathological outcomes of AD [25]. The gene discussed is MAPT; the disease is Alzheimer disease.